Malignant Urinary System Neoplasm — Trials

Malignant Urinary System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 887
Recruiting: 467
Ph III recruiting: 52
Growth YoY: +12.2%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (556)

clinicaltrialsPublishedShowing 51–100 of 1,505 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07667335	Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer	recruiting	Phase 1 / Phase 2	27	Fred Hutchinson Cancer CenterOTHER	1	Sep 17, 2026	clinicaltrials
NCT04940299	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	active not recruiting	Phase 2	35	M.D. Anderson Cancer CenterOTHER	1	Sep 16, 2026